{"nctId":"NCT00423605","briefTitle":"Safety and Efficacy Study of Xyrem速 (Sodium Oxybate) in Subjects With Fibromyalgia.","startDateStruct":{"date":"2006-12"},"conditions":["Fibromyalgia"],"count":560,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Xyrem速"]}],"interventions":[{"name":"Xyrem速","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject has qualified for and completed either study 06-009 (NCT00423813) or 06-008 (NCT00371137).\n* Subject is able, in the opinion of the investigator, to take Xyrem速 for approximately 9-1/2 months.\n\nExclusion Criteria:\n\n* Subject terminated early from either study 06-009 or 06-008.\n* Subject experienced any serious adverse event related to study drug in either study 06-009 or 06-008.\n* Subject, in the opinion of the investigator, experienced an adverse event in 06-009 or 06-008 that may prevent him/her from safely participating in this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reporting Adverse Events","description":"Number of subjects reporting adverse events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"498","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":560},"commonTop":["Nausea","Headache","Dizziness","Nasopharyngitis","Vomiting"]}}}